Perfume compositions

ABSTRACT

A perfume composition comprising a perfume component capable of inhibiting the production of odoriferous steroids by micro-organisms on the skin. The perfume component is capable of inhibiting the biotransformation of androstadienols to androstenones.

FIELD OF THE INVENTION

This invention relates to perfume compositions, to products containingsuch perfume compositions, and to the use of a perfume component orperfume composition to deliver a deodorant effect. In particular, theinvention relates to perfume components, mixtures thereof, and perfumecompositions for reducing or preventing body malodour.

BACKGROUND TO THE INVENTION

It is known that, at the point of secretion, sweat is odourless. Bodymalodour is the result of a variety of biotransformations of componentsof sweat by certain species of natural micro-organisms which live on thesurface of the skin. These transformations produce a number of volatileodoriferous compounds such as steroidal compounds (e.g. 16-androstenes),amongst others, which contribute to body malodour.

There are three types of personal product routinely used to combat bodymalodour: perfumes, antiperspirants and deodorants. Products such assoaps, shower gels, body washes and laundry products are also intendedto combat body malodour.

Perfumes may simply mask body malodour. However perfume compositionshave been disclosed which exhibit a deodorant action. EP-B-3172,EP-A-5618, U.S. Pat. No. 4,304,679, U.S. Pat. No. 4,322,308, U.S. Pat.No. 4,278,658, U.S. Pat. No. 4,134,838, U.S. Pat. No. 4,288,341 and U.S.Pat. No. 4,289,641 all describe perfume compositions which exhibit adeodorant action when applied to human skin or when included in alaundry product used to launder textiles.

Antiperspirants work by blocking the sweat glands, thereby reducingperspiration.

Antimicrobial agents used in deodorants are designed to reduce thepopulation, inhibit the growth or diminish the metabolic activities ofmicro-organisms living on the surface of the skin. Typical agents ofthis nature include ethanol and Triclosan(2′,4,4′-trichloro-2-hydroxydiphenyl ether) which are well known toexert antimicrobial effects. The use of common deodorant actives resultsin a non-selective antimicrobial action exerted upon most of the skin'snatural microflora. This is an undesirable disadvantage of suchdeodorant formulations, since the natural microflora provides aprotective barrier (colonisation resistance) against invasion bypotentially pathogenic bacteria.

U.S. Pat. No. 5,643,559 (Colgate-Palnolive Company) discloses deodorantactive materials having an effective amount of Zn²⁺ ions for inhibitingbacterial exoenzymes responsible for the production of axillarymalodour. The bacterial exoenzymes are further characterised as arylsulphatase or beta glucuronidase.

DE-4343265 (Henkel) describes deodorant compositions comprisingsaturated dioic acid (C3-C10) esters. The active inhibits a sweatdecomposing esterase and the compositions are said not to disturb theslin's natural microflora.

WO 94/07837 (Unichema) describes certain novel unsaturated dioic acidshaving between 8 and 22 carbon atoms. The potential use of these acidsto treat malodour is also described.

Gower et al. (J. Steroid Biochein. Molec. Biol., (1994) Vol. 48, No. 4,pp 409-418) discloses the importance of certain bacterial enzymesinvolved in bacterial steroid metabolism in the production ofodoriferous steroids, and proposes a series of interconversions betweensome of these metabolites.

Talalay, P.: Hydroxysteroid Dehydrogenases in The Enzymes, VII, 2nd Ed.,(Boyer, P., Lardy, H., and Myrback, K., eds.), Academic Press, NY, 177,1963, describes that 3[[alpha]] hydroxysteroid dehydrogenase fromPseudomonas testosteroni is inhibited by heavy metals andsulfhydryl-binding reducing agents.

Nakajin et al. (J. Steroid Biochem. Molec. Biol., (1991) January;38(1):95-9) discloses that the -conazole antifungal agents have a modeof action based on the inhibition of sterol metabolism. The activity ofthe enzyme (16-ene-C19-steroid synthesizing enzyme) responsible for theconversion of C21-steroids to 16-ene-C19-steroids, which was localizedon pig testicular microsomes, was inhibited by some typical imidazoleantifingal compounds such as clotrimazole, econazole, miconazole andketoconazole which are known to be universal inhibitors of cytochromeP450 dependent enzymes.

Lavallee et al. (J. Steroid Biochem. Molec. Biol. (1993) July;46(1):73-83) describes 20 beta-hydroxypregnenolone as a more potentinhibitor of 5,16-androstadien-3 beta-ol synthetase than of17-hydroxylase and for the latter enzyme activity, the Ki(app) was lowerthan that for 17-hydroxypregnenolone itself.

Watabe et al. (J. Biol. Chem. (1985) July 25; 260(15):8716-20) describesthat the C16-double bond of the steroid androsta-5,16-dien-3 beta-ol, isoxidized by male rat liver microsomes to 16 alpha,17alpha-epoxyandrost-5-en-3 beta-ol; 16 beta,17 beta-epoxyandrost-5-en-3beta-ol; androst-5-ene-3 beta,16 alpha,17 beta-triol; andandrost-5-ene-3 beta, 16 beta, 17 alpha-triol, and this transformationis strongly inhibited with CO.

WO 00/01355 and WO 00/01358 describe agents useful in preventing orreducing body malodour by inhibiting the production of odoriferoussteroids, wherein the agents inhibit the bacterial enzymes, bacterial4-ene reductase and/or 5 α-reductase. Examples of active agents aredescribed as dicarboxylic acids, phenyl compounds, monoterpenederivatives, sterols, flavonoids, steryl esters, 2,7-napthalenediol andoxyquinoline (WO 00/01355), and certain perfume components (WO00/01358).

Several steroids, notably 5α-androst-16-en-3-one (5α-androstenone),5α-androst-16-en-3α-ol (3α-androstenol) and androsta-4,16-dien-3-one(androstadienone) are known to be highly odorous in the context of humanaxillary odour. The biotransformations effected by a micro-organism onthe components of sweat to produce such odoriferous products orintermediates, occur via a number of possible, and typically,ill-defined metabolic pathways.

It has been suggested in the prior art (Gower et al) that odoroussteroids, e.g. androstenones, are formed by the biotransformation oftypically non-odorous steroids i.e. steroids present at levels below thethreshold of human olfactory detection, by the action of microorganismspresent on the skin surface. More particularly,5α-androsta-5,16-dien-3β-ol (androstadienol) was a source of the odorousandrostenones.

SUMMARY OF THE INVENTION

The present invention is based on extensive testing of perfumecomponents to determine whether a particular component is capable ofinhibiting the biotransformation of androstadienols to androstenones,particularly 5α-androst-16-en-3-one, and thus is capable of inhibitingthe production of odoriferous steroids by micro-organisms on the skinsurface. Based on this testing, perfume components were identified,which whilst known, possess hitherto unappreciated deodorant properties.The invention thus enables perfume compositions to be defined thatreduce or prevent body malodour.

Accordingly, in one aspect, the present invention provides a perfumecomposition comprising at least 30% by weight of one or more of thefollowing perfume components; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cis-jasmone, methyl octyl acetaldehyde, gamma-octalactone, octylacetate, pine American oil, peppermint (Chinese),1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.

The following perfume components are useful in the perfume compositionsdefined herein:

-   Armoise Tunisian oil;-   para-tert.butylphenylacetonitrile (also known as ‘Marenil’ where    MARENIL is a trade mark of Quest International);-   dihydrolinalol (3,7-dimethyloct-6-en-3-ol);-   N-ethyl-N-(3-methylphenyl)propionamide (also known as ‘Agarbois’    where AGARBOIS is a trade mark of Quest International);-   4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol;-   ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate;-   2-ethyl-N-methyl-N-(3-methylphenyl)butanamide (also known as    ‘Paradisamide’ where PARADISAMIDE is a trade mark of Quest    International);-   dihydromyrcenol (2,6-dimethyl-7-octen-2-ol);-   (4-isopropylcyclohexyl)methanol;-   3-methyl-5-phenylpentan-1-ol (also known as ‘Mefrosol’ where    MEFROSOL is a trade mark of Quest International);-   2,2,2-trichloro-1-phenylethyl acetate (also known as Rosacetone or    Roseacetone);-   isobornyl acetate;-   allyl amyl glycolate (‘2-methylbutyloxyacetic acid, 2-propenyl    ester’);-   alpha-terpineol;-   acetyl cedrene (also known as ‘Lixetone’ where LIXETONE is a trade    mark of Quest International);-   tetrahydrogeraniol;-   citronellal;-   cuminic aldehyde (para-isopropylbenzaldehyde);-   cis-jasmone;-   methyl octyl acetaldehyde (2-methyldecenal);-   gamma-octalactone (5-butyldihydrofuran-2(3H)-one);-   octyl acetate;-   pine American oil;-   peppermint (Chinese);-   1,3,3-trimethyl-2-norbornanyl acetate (fenchyl acetate);-   1,3,3-trimethyl-2-norbornanol (fenchyl alcohol); gamma-nonalactone;-   octahydro-2H-chromen-2-one (also known as ‘Octahydrocoumarin’ where    OCTAHYDROCOUMARIN is a trade mark of Quest International);-   cis-4-decenal;-   3-(3-isopropylphenyl)butanal.

The term “perfume component” is used herein to represent a materialwhich is added to a perfume composition to contribute to the olfactiveproperties of the composition. A perfume component can be acceptablyemployed to provide odour contributions to the overall hedonicperformance of products. Typically, a perfume component will begenerally recognised as possessing odours in its own right, will berelatively volatile and often has a molecular weight within the range100 to 300. Typical materials which are perfume components are describedin “Perfume and Flavour Chemicals”, Volumes I and II (Steffan Arctander,1969).

For the purposes of the present invention, by perfume composition ismeant a mixture of individual perfume components, and optionally one ormore suitable diluents, which is used to impart a desired odour to theskin and/or product for which an agreeable odour is indispensable ordesirable. Commonly used diluents are benzyl benzoate, diethylphthalate, dipropylene glycol and isopropyl myristate. The concentrationof perfume components referred to herein is relative to the totalconcentration of perfume components present in the composition, i.e.excludes any diluents.

To deliver high deodorant effects the perfume component(s) arepreferably present in a perfume composition in an amount of 40% byweight of the total weight of the perfume composition, more preferablyat least 45%, and most preferably at least 60%.

Additionally, or alternatively, a perfume composition in accordance withthe present invention preferably comprises at least 3, more preferablyat least 5, and even more preferably at least 10 of the specifiedperfume components.

Thus, in a further aspect, the present invention provides a perfumecomposition comprising at least 3 of the following perfume components;Armoise Tunisian oil, para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cisjasmone, methyl octyl acetaldehyde, gamma-octalactone, octyl acetate,pine American oil, peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol,gamma-nonalactone, octahydro-2H-chromen-2-one, cis-4-decenal,3-(3-isopropylphenyl)butanal.

The perfume components useful herein in a perfume composition may beincorporated into deodorant products which include, but are not limitedto, body deodorants and antiperspirants including roll ons, sprays, gelproducts, stick deodorants, antiperspirants, shampoos, soaps, showergels, talcum powder, hand creams, skin conditioners, sunscreens, sun tanlotions, and hair conditioners.

Thus, in an even further aspect, the present invention provides adeodorant product comprising a perfume composition in accordance withthe invention.

A deodorant product preferably comprises at least 0.05% to 4%, morepreferably 0.1% to 2% of a perfume composition by weight of thedeodorant product.

The perfume components useful herein may also be conveniently employedfor deodorant purposes by incorporation into other products, e.g.laundry and household products such as rinse conditioners, householdcleaners and detergent cleaners. The perfume components can beincorporated into textiles themselves during their production usingtechniques known in the art, to provide deodorant protection.

In a preferred embodiment of the present invention, an Odour ReductionValue, measured in human axillae as described in Example 4, of at least10%, more preferably at least 30%, and particularly at least 45% isobtained.

One or more of the perfume components useful herein may be mixed withother perfume components, e.g. perfume components of the prior arthaving deodorant properties, to formulate perfume compositions withdesired deodorant and hedonistic properties.

In one such embodiment, there is provided a perfume composition asdefined herein, wherein the perfume composition additionally comprisesat least 15% by weight, preferably at least 30% by weight, of one ormore of the following perfume components: acetyl di-iso-amylene, acetyltributyl citrate, aldehyde C10 (i.e. decenal), Amber AB 358 (availablefrom Quest International), amyl salicylate, anisyl acetate, Azarbre*,benzyl salicylate, cis-3-hexenyl salicylate, citral, citronellol, cloveleaf distilled, coriander, cyclamen aldehyde, decen-1-ol,dihydroeugenol, diphenylmethane, Dupical*, Empetaal*, geraniol, helionali.e. 2-methyl-3-(3,4-methylene-dioxyphenyl)propanal), lonones (alpha-and beta-), Jasmacyclene*, 3-(4-methyl-4-hydroxyamyl)-3-cyclohexenecarboxaldehyde, methyl eugenol, methyl isoeugenol, Ortholate*,para-cresyl methyl ether, 2-phenylethyl alcohol, para tert. butylcyclohexyl acetate, rose oxide (racemic), styrallyl acetate,tetrahydrolinalol, and vanillin; wherein all asterisked materials aretrade marks of Quest International.

In a preferred embodiment, there is provided a perfume compositioncomprising:

-   (i) at least 30% by weight of the perfume composition of at least 3    of the following perfume components:    N-ethyl-N-(3-methylphenyl)propionamide,    2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol,    (4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,    2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amyl    glycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,    citronellal, cuminic aldehyde, cis-jasmone, pine American oil,    peppermint (Chinese), 1,3,3-trmethyl-2-norbornanol,    gamma-nonalactone, octahydro-2H-chromen-2-one, cis-4-decenal,    3-(3-isopropylphenyl)butanal; and-   (ii) at least 30% by weight of the perfume composition of one or    more of the following perfume components: acetyl di-iso-amylene,    acetyl tributyl citrate, aldehyde C10, Amber AB 358, amyl    salicylate, anisyl acetate, Azarbre, benzyl salicylate,    cis-3-hexenyl salicylate, citral, citronellol, clove leaf distilled,    coriander, cyclamen aldehyde, decen-101, dihydroeugenol,    diphenylmethane, Dupical, Empetaal, geraniol, helional,    alpha-ionone, beta-ionone, Jasmacyclene,    3-(4-methyl-4-hydroxyamyl)-3-cyclohexene carboxaldehyde, methyl    eugenol, methyl isoeugenol, Ortholate, para-cresyl methyl ether,    2-phenylethyl alcohol, para tert. butyl cyclohexyl acetate, rose    oxide, styrallyl acetate, tetrahydrolinalol, and vanillin.

Also included within the scope of the invention is a method,particularly a cosmetic method, for reducing or preventing body malodourby topically applying to human skin a composition comprising a perfumecomponent selected from at least one of the following; Armoise Tunisianoil, para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cisjasmone, methyl octyl acetaldehyde, gamma-octalactone, octyl acetate,pine American oil, peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol,gamma-nonalactone, octahydro-2H-chromen-2-one, cis-4-decenal,3-(3-isopropylphenyl)butanal.

Preferably, the composition is a perfume composition.

Preferred perfume components for use in the method as defined above areselected from one or more of the following; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.

The method thus comprises topically applying to human skin, one or moreof the specified perfume components which is(are) capable of reducing orpreventing body malodour by inhibiting the production of odoriferoussteroids by micro-organisms present on the skin surface, wherein theperfume component is capable of inhibiting the biotransformation ofandrostadienols to androstenones. Typically, the specified perfumecomponents inhibit the production of odoriferous steroids by Coryneformbacteria present on the skin surface, particularly Corynebacterium spp.The inhibitory effect of the perfume components useful herein can beachieved antimicrobially or sub-lethally.

The antimicrobial effects of compounds, e.g. perfume components, areusually divided into two types; they can either inhibit bacterial growth(bacteriostatic action) or alternatively they can act by directlykilling existing viable bacteria (bactericidal action).

The bacteriostatic action of a compound “X” such as a perfume component,can be tested for in vitro by inoculating a standard, small number ofbacteria into broths containing an appropriate range of concentrationsof X. The broths are then incubated for a suitable time, and growthcompared with a control containing no inhibitor. The broth containingthe lowest concentration of X which shows reduction of growth comparedto the control broth is defined as the minimum inhibitory concentration(MIC).

The determination of bactericidal action of a compound “Y” such as aperfume component is carried out by adding various concentrations ofcompound Y to replicate broths containing relatively high, standardnumbers of bacteria. After a certain period allowing any antibacterialactivity to take place, aliquots of the bacterial cultures are diluted(usually in 10-fold steps) and dispensed onto agar plates. The platesare incubated with the expectation that each viable cell should producea visible colony. The numbers of colonies are multiplied to take accountof the dilution, to establish the number of viable cells in the broths.Once again, the broths containing compound Y are compared with anuntreated control broth. The minimum concentration of compound Y whichcauses a reduction in the viable number of bacteria is the minimumbactericidal concentration (MBC). MBC can also be expressed in terms ofthe MBC required to produce a certain degree of killing (for example, a3 log₁₀ reduction in count, equivalent to a 99.9% kill). Still further,the MBC can be expressed in kinetic terms—the time of exposure to anagent required for a given MBC effect.

A further possibility is that the process of inhibition could besub-lethal (or sub-MIC), whereby the perfume components interfere withthe metabolic process, but typically do not inhibit bacterial growth.

Preferably, the bacterial production of odoriferous steroids is reducedby at least 50%, more preferably by at least 70%, particularly by atleast 80%, and especially by at least 90%. Three modes of achieving areduction of odoriferous steroid production are possible. In the firstmode, the perfume components (or perfume compositions) may act by direct(overt antimicrobial) killing of skin bacteria, e.g. by more than10-fold; in the second mode, they may act on odoriferous steroidgeneration whilst maintaining a microbial cell viability of at least70%; in the third mode, they may inhibit odoriferous steroid generation,at a concentration below the minimum inhibitory concentration (MIC),determined as described in Example 1 below. The third mode is preferred,since this provides malodour counteraction benefits, whilst leaving thenatural skin microflora undisturbed. Thus, preferably the bacterialproduction of odoriferous steroids can be reduced or eliminated withoutsignificantly disturbing the skin's natural microflora. This may beachieved by inhibiting the bacterial enzymes responsible for theproduction of odoriferous steroids, in particular the androstenones suchas 5α-androst-16-en-3-one.

In an even further aspect the present invention provides use of one ormore of the following perfume components; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal,as a deodorant active.

In a still further aspect the present invention provides use of one ormore of the following perfume components; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis4-decenal, 3-(3-isopropylphenyl)butanal,in the manufacture of a composition for reducing or preventing bodymalodour.

Based on the MIC value evaluated for a particular perfume component, itis possible to select and combine those perfume components having lowMIC values which are likely to be antimicrobially active, and toformulate a deodorant product which has some degree of anti-microbialactivity. An example of this is a product including an antimicrobiallyeffective amount, typically between 0.05% and 4% by weight, preferablybetween 0.1% and 2% by weight, more preferably between 0.5% and 1.5% byweight, of a perfume composition comprising at least 30% by weight ofone or more of the following perfume components:

-   N-ethyl-N-(3-methylphenyl)propionamide;-   3-methyl-5-phenylpentan-1-ol;-   2,2,2-trichloro-1-phenylethyl acetate;-   pine American oil;-   cis-4-decenal;-   4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol;-   cuminic aldehyde;-   methyl octyl acetaldehyde;-   Armoise Tunisian oil;-   dihydromyrcenol;-   allyl amyl glycolate;-   alpha-terpineol;-   cis-jasmone;-   peppermint (Chinese);-   gamma-nonalactone;-   octahydro-2H-chromen-2-one;-   para-tert.butylphenylacetonitrile;-   dihydrolinalol;-   tetrahydrogeraniol; and-   1,3,3-trimethyl-2-norbornanol;    optionally in combination with perfume components having known high    antimicrobial activity such as phenylethyl alcohol, geraniol,    cinnamic acid, benzyl alcohol, and citral.

Likewise, it is also possible to select and combine those perfumecomponents with higher MIC values which are likely to sub-lethallyinhibit odoriferous steroid generation, and to formulate a deodorantproduct with minimal antimicrobial activity. Such a product may include,for example, appropriate levels of a perfume composition, typicallybetween 0.05% and 4% by weight of the deodorant product of a perfumecomposition, preferably between 0.1% and 2% by weight, more preferablybetween 0.5% and 1.5% by weight, the perfume composition comprising atleast 30% by weight of one or more of the following perfume components:

-   ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate;-   2-ethyl-N-methyl-N-(3-methylphenyl)butanamide;-   (4-isopropylcyclohexyl)methanol;-   isobornyl acetate;-   acetyl cedrene;-   citronellal;-   gamma-octalactone;-   octyl acetate;-   1,3,3-trimethyl-2-norbornanyl acetate;-   3-(3-isopropylphenyl)butanal.

The invention also provides the use of a perfume component to inhibitthe biotransformation of androstadienols to androstenones, in particularthe biotransformation of androsta-5,16-dien-3β-ol to5α-androst-16-en-3-one.

The invention further provides the use of a perfume composition,comprising at least 30% by weight of one or more perfume componentscapable of inhibiting the biotransformation of androstadienols toandrostenones, to reduce body malodour.

The invention further provides the use of a deodorant product,comprising a perfume component, to reduce body malodour by inhibitingthe biotransformation of androstadienols to androstenones.

The invention still further provides a method of producing a perfumecomposition which comprises (i) evaluating perfume components on theability to inhibit the biotransformation of androstadienols toandrostenones, (ii) selecting perfume components on the ability toinhibit the biotransformation of androstadienols to androstenones, and(iii) mixing together two or more of said selected perfume components,optionally with other perfume components.

The invention still further provides use of a perfume compositioncomprising a perfume component to reduce body malodour, characterised inthat the composition comprises at least 30% by weight of at least one ofthe perfume components specified in the paragraph bridging pages 5 and 6above.

The invention is illustrated by the following examples.

EXAMPLE 1 Minimum Inhibitory Concentration (MIC)

The minimum inhibitory concentration of a perfume component wasdetermined by the following method.

A culture of the test strain—Corynebacterium xerosis NCTC 7243 (NationalCollection of Type Cultures, Public Health Laboratory Service, CentralPublic Health Laboratory, 61 Colindale Avenue, London, NW9 5HT) wasgrown in 100 ml of tryptone soya broth (TSB) (Oxoid, Basingstoke, UK)for 16-24 hours, in a shaken flask at 37° C. The culture was thendiluted in sterile 0.1% TSB (Oxoid, Basingstoke, UK) to give aconcentration of bacteria of approximately 10⁶ colony forming units(cfu) per ml.

Perfume or perfume component samples were diluted in sterile TSB to givestock solutions with final concentrations of 40,000 ppm (perfume) or20,000 ppm (perfume component). Each row of a standard, 96-well plasticmicrotitre plate (labelled A-H) was allocated to one sample, thus eightsamples per plate. Row H contained only TSB for use as a bacterialcontrol to indicate the degree of turbidity resulting from bacterialgrowth in the absence of any test material. Aseptically, 200 μl of theinitial dilution of perfume/perfume component was transferred to the1^(st) and 7^(th) well of the appropriate row. All other test wells werefilled with 100 μl of sterile TSB using an 8-channel micro-pipette. Thecontents of each of the wells in column 1 were mixed by sucking samplesup and down in pipette tips, before 100 μl was transferred to column 2.The same sterile pipette tips were used to transfer 100 μl of each wellin column 7, into the appropriate well in column 8. This set of eighttips was then discarded into disinfectant solution. Using eight fresh,sterile tips the process was repeated by transferring 100 μl from column2 into column 3 (and 8 into 9). The process was continued until allwells in columns 6 and 12 contained 2001 μl. After mixing, 100 μl wasdiscarded from wells in columns 6 and 12 to waste. Finally, 100 μl ofpre-diluted bacterial culture (approx. 10⁶ cfu/ml) was added, thusgiving 200 μl final volume in each well.

A blank plate was prepared for each set of eight samples in exactly thesame way, except that 100 μl of sterile 0.1% TSB was added instead ofbacterial culture. This plate was used as the control plate againstwhich the test plate(s) could be read. Test and control plates weresealed using autoclave tape and incubated for 18-30 hours at 37° C.

The microtitre plate reader (Model MRX, Dynatech Laboratories) waspreset to gently agitate the plates and mix the contents. The absorbanceat 540 nm (hereinafter referred to for brevity and simplicity as “A₅₄₀”)was used as a measure of turbidity resulting from bacterial growth. Thecontrol, un-inoculated plate for each set of samples was read first, andthe plate reader then programmed to use the control readings to blankall other plate readings for the inoculated plates for the same set oftest materials (i.e. removing turbidity due to perfume and possiblecolour changes during incubation). Thus, the corrected readingsgenerated were absorbances resulting from turbidity from bacterialgrowth. The MIC was taken as the concentration of perfume/perfumecomponent required to inhibit growth so that the change in absorbanceduring the incubation period was <0.2 A₅₄₀.

EXAMPLE 2 Steroid Biotransformation Assay

The ability of perfume components and mixtures of these components toinhibit the biotransformation of androstadienols to androstenones wasdetermined in vitro using the method described below.

Corynebacterium sp. NCIMB 41018 (National Collections Of Industrial,Food and Marine Bacteria, 23 St Machar Drive, Aberdeen, AB24 3RY,Scotland, UK) (also known as Corynebacterium G41) was grown in 100 ml ofTSB supplemented with 0.1% w/v yeast extract (Oxoid) and 0.1% v/v Tween80 (Sigma, Poole, UK) for 18-30 hours, in a shaken flask at 37° C. Thisculture was then harvested by centrifugation, and resuspended in 100 mlof biotransformation medium (consisting of a sterile semi-syntheticbasal medium containing KH₂PO₄ 1.6 g/l; (NH₄)₂HPO₄ 5 g/l; Na₂SO₄ 0.38g/l; yeast nitrogen base 3.35 g/l; yeast extract 0.5 g/l; Tween 80 0.2g/l; Triton X-100 0.2 g/l and MgCl₂.6H₂O 0.5 g/l).

Substrate androsta-5,16-dien-3β-ol (50 mg/assay) was added to thebacterial suspension and incubated for 72 hours at 37° C. with agitation(at 220-250 rpm) in a 250 ml, baffled-Erlenmeyer flask.

Following biotransformation of androsta-5,16-dien-3β-ol toandrost-16-en-3-one the bacteria were harvested and the cell pelletdried in air and then under vacuum.

The dried cells were then crushed and suspended in 100 ml of a mixtureof diethyl ether, chloroform, ethanol, ethyl acetate and acetone(1:2:1:1:1 v/v, respectively), and stirred for 16 hours. The supernatantwas then reduced to half its volume, filtered and evaporated at 30° C.and 15 mmHg pressure. The resulting residue was re-dissolved in 5 ml ARgrade methanol. Following sonication, the sample was analysed by HPLC ona Phenomenex Luna 5 micron, C18 reverse-phase HPLC column coupled to aMillipore-Waters 600E System Controller. Elute was passed through aMillipore-Waters 486 Tuneable absorbance detector and relative amountsof the steroid metabolite was determined by a Hewlett Packard HP 3396AIntegrator printer. The composition of the HPLC mobile phase was aqueousmethanol. The flow rate was 0.8 ml/min. Calibration curves were used todetermine the molar quantities of pure steroid metabolites inbiotransformed mixtures and hence the conversions.

Metabolites were analysed by HPLC-MS to determine their structure.

The biotransformation of androsta-5,16-dien-3β-ol to5α-androst-16-en-3-one by Corynebacterium NCIMB 41018 is as shown below:

It will be appreciated that the Coryneform bacteria used in Examples 1and 2 are not the same strains. This is because the nutrient Tween-80required for growth by Corynebacterium NCIMB 41018 (Example 2) is notsuitable for inclusion in the growth medium used for MIC testing. Asdescribed above, during MIC testing, measurements are taken of theturbidity resulting from bacterial growth. Tween-80 when dissolved in anaqueous growth medium turns the medium cloudy. Thus, the addition ofTween-80 to a growth medium to be used for MIC testing would interferewith the readings, making an accurate determination of the turbidity dueto bacterial growth impossible. Thus, a similar axillary Corynebacteriumstrain (C. xerosis NCTC 7243) is used in the MIC test, which does notrequire this nutrient for growth. The susceptibility of Corynebacteriumxerosis NCTC 7243 to a variety of perfume components is likely to bevery similar to that of Corynebacterium NCI 41018 as they are from thesame genus.

EXAMPLE 3

INGREDIENT w/w % Perfume A: Composition % by weight. AGARBOIS (Q)  15*CINNAMIC ALCOHOL  2 COUMARIN  1 DIHYDROMYRCENOL  8* GERANIUM OIL  2HABANOLIDE (F)  3 LILIAL (G)  10 (4-ISOPROPYLCYCLOHEXYL)METHANOL  2*MEFROSOL (Q)  5* METHYL ANTHRANILATE  1 METHYL CEDRYL KETONE  4 METHYLDIHYDROJASMONATE (Q)  10 PHENYL ETHYL ALCOHOL  15 ROSACETONE  5*VANILLIN 5% IN DEP  17 total 100.00% Perfume B: Composition % by weight.ACETYL CEDRENE  7.5* AGARBOIS (Q)  6* ALDEHYDE MNA 10% DEP  1 ALLYL AMYLGLYCOLATE (Q)  2.2* AMBER CORE (Q)  0.5 ARMOISE TUNISIAN  0.4* BANGALOL(Q)  0.5 BENZYL SALICYLATE (Q)  8.5 BERGAMOT OIL  7.5 BOURGEONAL (Q) 0.5 CARVONE LAEVO (Q) 10% DEP  1 CEDARWOOD VIRGINIAN OIL  1.1cis-3-HEXENYL SALICYLATE  1.5 CISTULATE (Q) 10% DEP  2 CORIANDER  0.3COUMARIN  0.6 CYCLOHEXYLOXYACETIC ACID, ALLYL ESTER  0.2CYCLOPENTADECANOLIDE  2.2 DIHYDROMYRCENOL (Q)  13* ETHYLENE BRASSYLATE 1.5 GERANIUM OIL  1.4 HELIONAL  0.3 HEXYL CINNAMIC ALDEHYDE  2.5 IONONE(Q)  1.5 ISO AMBOIS (Q)  7.5 ISO BORNYL ACETATE  0.6* ISOBORNYLCYCLOHEXANOL  1.5 LAVANDIN OIL  0.3 LILIAL (G)  6.8 METHYL CHAVICOL  1.2METHYL DIHYDROJASMONATE SUPER (Q)  6.4 MOSS OAKMOSS SYNTHETIC  0.2NUTMEG PURE  0.2 PEPPERMINT CHINESE 10% DEP  3.5* PETITGRAIN PARAGUAY 0.2 ROSE OXIDE RACEMIC 10% DEP  0.5 STYRALLYL ACETATE  0.4 TERPINEOLALPHA  2.5* TETRAHYDROLINALOL  4.5 total 100.00% Perfume C: Composition% by weight. ACETYL CEDRENE (Q)  7* AGARBOIS (Q)  15* ALDEHYDE MNA 10%DEP  2.5 BENZYL SALICYLATE (Q)  6.4 cis-JASMONE  1.2* CITRONELLAL  2.2*COUMARIN  1.3 CYCLOPENTADECANOLIDE  6.6 DIHYDROMYRCENOL (Q)  8.5*ETHYLENE BRASSYLATE  2.3 HEXYL CINNAMIC ALDEHYDE  3.5 ISO AMBOIS (Q)  7ISO BORNYL ACETATE  2.6* LILIAL (G)  5.4 MARENIL (Q)  1.3* MEFROSOL (Q) 5.4* METHYL DIHYDROJASMONATE SUPER (Q)  7.6 PETITGRAIN PARAGUAY  1.2TERPINEOL ALPHA  3* TETRAHYDROGERANIOL  10* total 100.00% Perfume D:Composition % by weight. 4-(5-ETHYLBICYCLO[2.2.1]HEPTYL-2)-  1.2*CYCLOHEXANOL ACETYL CEDRENE (Q)  5.3* ALDEHYDE C11 (UNDECYLENICALDEHYDE)  1.4 10% DEP ALDEHYDE MNA 10% DEP  0.8 ALLYL AMYL GLYCOLATE(Q)  1.3* ARMOISE TUNISIAN  0.2* BANGALOL (Q)  0.3 BENZYL SALICYLATE (Q) 5.1 BERGAMOT OIL  4.8 CEDARWOOD VIRGINIAN OIL  1.1 CITRONELLAL  2*CITRONELLOL  6.9 CYCLOPENTADECANOLIDE  2.3 DIHYDROMYRCENOL (Q)  15.8*ETHYLENE BRASSYLATE  8.8 FENCHYL ACETATE  2.5* HEXYL CINNAMIC ALDEHYDE 5.1 IONONE (Q)  3.5 ISOBORNYL CYCLOHEXANOL  1.8 METHYL DIHYDROJASMONATESUPER (Q)  5.5 PARA TERT BUTYL CYCLOHEXYL ACETATE  3.4 PARADISAMIDE (Q) 2.8* PEPPERMINT CHINESE 10% DEP  4.3* PHENYLETHYL ALCOHOL  6 ROSE OXIDERACEMIC 10% DEP  2.1 ROSEACETONE  3.7* TETRAHYDROGERANIOL  2* total100.00% Perfume E: Composition % by weight.4-(5-ETHYLBICYCLO[2.2.1]HEPTYL-2)-  2.3* CYCLOHEXANOL AGARBOIS (Q)  4*ALDEHYDE C11 (UNDECYLENIC ALDEHYDE)  1.2 10% DEP AMBER CORE (Q)  4.3CARVONE LAEVO (Q) 10% DEP  3.8 CEDARWOOD VIRGINIAN OIL  1.8 cis-JASMONE 0.5* CISTULATE (Q) 10% DEP  0.9 CITRONELLOL  3.6 CORIANDER  0.2COUMARIN  0.9 DIHYDROMYRCENOL (Q)  4.5* ETHYLENE BRASSYLATE  6.2 FENCHYLACETATE  3.6* HEXYL CINNAMIC ALDEHYDE  6.8 HEXYL SALICYLATE  7.5 LILIAL(G)  6.5 MARENIL (Q)  2.6* METHYL CHAVICOL  0.4 METHYL DIHYDROJASMONATESUPER (Q)  3.5 METHYL OCTYL ACETALDEHYDE 10% DEP  5.5* MOSS OAKMOSSSYNTHETIC  0.2 PEPPERMINT CHINESE 10% DEP  34* PETITGRAIN PARAGUAY  2.1PHENYLETHYL ALCOHOL  7.1 TERPINEOL ALPHA  6.4* TETRAHYDROGERANIOL  8.2*TETRAHYDROLINALOL  2 total 100.00%*Materials of the inventionTrademarks:‘Q’ = Quest International;‘F’ = Firmenich;‘G’ = Givaudan

EXAMPLE 4 Product Base Examples

The following are typical formulations of deodorant products whichcomprise a perfume composition in accordance with the invention. Theseformulations are made by methods common in the art.

1. Deodorant Sticks Content (% by weight) Ingredient Formulation 1AFormulation 1B Ethanol 8.0 Sodium Stearate 7.0 6.0 Propylene glycol 70.012.0 Perfume 1.5 2.0 PPG-3 Myristyl ether 28.0 PPG-10 Cetyl ether 10.0Cyclomethicone 34.0 Water 21.5

2. Aerosols Content % by weight Ingredient Formulation 2A Formulation 2BEthanol B up to 100 Propylene glycol as required Perfume  2.0 1.2Chlorhydrol microdry 31.8 Silicone Fluid DC344 up to 100 Bentone gel IPP13.65 Dimethyl ether 20.0 Concentrate 22.0 Water 23.0 Content % byweight Ingredient Formulation 2C Ethanol (Denatured) up to 100 Perfume 1.0 DC345 Fluid^((i)) 15.0 Hydrocarbon Propellant, 30 psig^((ii)) 60.0^((i))DC345 fluid (INCI name - CYCLOPENTA-SILOXANE) is a volatile, lowviscosity, silicone fluid. It is non-greasy providing a light, silkyfeel on the skin.^((ii))The hydrocarbon propellant can be any deodorised blend ofn-butane, n-propane and isobutane having a pressure of 30 pounds persquare inch gauge or 2.109 kg/cm² gauge (308 kPa).

3. Roll ons Content % by weight Ingredient Formulation 3A Formulation 3BEthanol to 100% 60.0 Klucel MF 0.65 Cremphor RM410 0.5 Perfume 0.5 1.0AZTC* 20.0 Cyclomethicone 68.0 Dimethicone 5.0 Silica 2.5 Water 37.85*Aluminium zirconium tetrachlorohydro glycinate

Perfume compositions A to E embodying this invention (see Example 3above) were prepared and tested for deodorant action in underarmproducts, particularly an aerosol product of Formulation 2C, using anOdour Reduction Value test generally as described in U.S. Pat. No.4,278,658.

The Odour Reduction Value test was carried out using a panel of 40Caucasian male subjects. A standard quantity (approximately 1.75 g) ofan aerosol product containing one of the perfume compositions or anunperfumed control was applied to the axillae of the panel members inaccordance with a statistical design.

After a period of five hours, the underarm odour was judged by threetrained female assessors who scored the odour intensity in accordancewith a 0 to 5 scale, as shown below: Conc. of aqueous Score Odour levelisovaleric acid (ml/I) 0 No odour 0 1 Slight 0.013 2 Definite 0.053 3Moderate 0.22 4 Strong 0.87 5 Very Strong 3.57

Average scores for each test product and the control product were thendetermined. The score for each test product was subtracted from thescore for the control product and the reduction expressed as apercentage to give the Odour Reduction Value (%).

Perfume compositions A to E were all found to exhibit significantdeodorant activity.

For example, Perfume A contains 35% of perfume components of theinvention. Excluding diluents, this percentage increases to 42.2%. Forthis perfume, present at 1.0% in an aerosol product of Formulation 2Cabove, the Odour Reduction Value (%) compared to an unperfumed controlwas 48.3% (5 hours).

The Odour Reduction Value (%) compared to an unperfumed control forPerfume B was 44.6% (5 hours), for Perfume C 35.3% (5 hours) and forPerfume E 28.2% (5 hours).

1. A perfume composition comprising at least 30% by weight of one ormore of the following perfume components; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cis-jasmone, methyl octyl acetaldehyde, gamma-octalactone, octylacetate, pine American oil, peppermint (Chinese),1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.2. A perfume composition comprising at least 3 of the following perfumecomponents; Armoise tunisian oil, para-tert.butylphenylacetonitrile,dihydrolinalol, n-ethyl-n-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-n-methyl-n-(3-methylphenyl)butanamide, dihydromyrcenol,(4-isopropylcyclohexy)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alphaterpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cis-jasmone, methyl octyl acetaldehyde, gamma-octalactone, octylacetate, pine american oil, peppermint (chinese),1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.3. A perfume composition according to claim 2, wherein the perfumecomposition comprises at least 30% by weight of at least 3 of thespecified perfume components.
 4. A deodorant product comprising aperfume composition according to any one of claims 1, 2 or
 3. 5. Use ofone or more of the following perfume components; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal,as a deodorant active.
 6. Use of one or more of the following perfumecomponents; Armoise Tunisian oil, para-tert.butylphenylacetonitrile,dihydrolinalol, N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis4-decenal, 3-(3-isopropylphenyl)butanal,in the manufacture of a composition for reducing or preventing bodymalodour.
 7. A method for reducing or preventing body malodour bytopically applying to human skin a composition comprising a perfumecomponent selected from at least one of the following; Armoise Tunisianoil, para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide, dihydromyrcenol, (4isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, alpha-terpineol, acetyl cedrene, tetrahydrogeraniol,citronellal, cuminic aldehyde, 1,3,3-trimethyl-2-norbornanyl acetate,cis-jasmone, methyl octyl acetaldehyde, gamma-octalactone, octylacetate, pine American oil, peppermint (Chinese),1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.8. A method according to claim 7 wherein the perfume component isselected from at least one of the following; Armoise Tunisian oil,para-tert.butylphenylacetonitrile, dihydrolinalol,N-ethyl-N-(3-methylphenyl)propionamide,4-(5-ethylbicyclo[2.2.1]heptyl-2)-cyclohexanol,ethyltricyclo[5.2.1.0{2,6}]decane-2-carboxylate,2-ethyl-N-methyl-N-(3-methylphenyl)butanamide,(4-isopropylcyclohexyl)methanol, 3-methyl-5-phenylpentan-1-ol,2,2,2-trichloro-1-phenylethyl acetate, isobornyl acetate, allyl amylglycolate, acetyl cedrene, tetrahydrogeraniol, citronellal, cuminicaldehyde, 1,3,3-trimethyl-2-norbornanyl acetate, cis-jasmone, methyloctyl acetaldehyde, gamma-octalactone, octyl acetate, pine American oil,peppermint (Chinese), 1,3,3-trimethyl-2-norbornanol, gamma-nonalactone,octahydro-2H-chromen-2-one, cis-4-decenal, 3-(3-isopropylphenyl)butanal.9. A method according to claim 7 or 8, wherein the composition is aperfume composition.
 10. A method according to claim 9, wherein theperfume composition comprises at least 30% by weight of at least one ofthe specified perfume components.